These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Potential implications of long-acting GLP-1 receptor agonists for critically ill. Wang L; Yang H; Xia X; Wang B; Wu Q Crit Care; 2024 May; 28(1):159. PubMed ID: 38741192 [No Abstract] [Full Text] [Related]
64. Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission. Figueredo Y; Cottone C; Ferreira T; Gonzalez J; Iacobellis G Cureus; 2023 Jan; 15(1):e34331. PubMed ID: 36865977 [TBL] [Abstract][Full Text] [Related]
65. Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices. Galindo RJ; Dhatariya K; Gomez-Peralta F; Umpierrez GE Curr Diab Rep; 2022 Jun; 22(6):237-246. PubMed ID: 35507117 [TBL] [Abstract][Full Text] [Related]
66. GLP-1a: Going beyond Traditional Use. Laurindo LF; Barbalho SM; Guiguer EL; da Silva Soares de Souza M; de Souza GA; Fidalgo TM; Araújo AC; de Souza Gonzaga HF; de Bortoli Teixeira D; de Oliveira Silva Ullmann T; Sloan KP; Sloan LA Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054924 [TBL] [Abstract][Full Text] [Related]
67. COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy. Xie L; Zhang Z; Wang Q; Chen Y; Lu D; Wu W Front Endocrinol (Lausanne); 2021; 12():772865. PubMed ID: 34867819 [TBL] [Abstract][Full Text] [Related]
68. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection. Bielka W; Przezak A; Pawlik A Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299225 [TBL] [Abstract][Full Text] [Related]
69. Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections. Sun B; Huang S; Zhou J Front Pharmacol; 2020; 11():592439. PubMed ID: 33584268 [TBL] [Abstract][Full Text] [Related]
70. Dissecting the interaction between COVID-19 and diabetes mellitus. Chee YJ; Tan SK; Yeoh E J Diabetes Investig; 2020 Sep; 11(5):1104-1114. PubMed ID: 32558211 [TBL] [Abstract][Full Text] [Related]
71. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Østergaard L; Frandsen CS; Madsbad S Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176 [TBL] [Abstract][Full Text] [Related]
72. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. Boyle JG; Livingstone R; Petrie JR Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742 [TBL] [Abstract][Full Text] [Related]
73. The use of GLP-1 receptor agonists in hospitalised patients: An untapped potential. Mustafa OG; Whyte MB Diabetes Metab Res Rev; 2019 Nov; 35(8):e3191. PubMed ID: 31141838 [TBL] [Abstract][Full Text] [Related]
74. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Gentilella R; Pechtner V; Corcos A; Consoli A Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747 [TBL] [Abstract][Full Text] [Related]
76. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]